16:45 , Feb 17, 2017 |  BC Week In Review  |  Company News

AMAG, Endoceutics deal

Endoceutics granted AMAG exclusive, U.S. rights to commercialize Intrarosa prasterone. The product is approved to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), in postmenopausal women. AMAG expects to launch...
22:45 , Nov 17, 2016 |  BC Week In Review  |  Clinical News

Intrarosa regulatory update

FDA approved an NDA for Intrarosa prasterone from Endoceutics to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), in postmenopausal women. The once-daily vaginal insert delivers localized prasterone, an androgen...
07:00 , Jul 2, 2007 |  BioCentury  |  Finance

Calling card put away

When GlaxoSmithKline gained an exclusive option in 2004 to all of Theravance's programs through August 2007, the initial worry among investors was that THRX had become a hostage to the pharma giant. That turned out...
01:17 , Jun 29, 2007 |  BC Extra  |  Financial News

EndoCeutics pulls IPO

EndoCeutics (Quebec City, Quebec) withdrew its IPO, citing market conditions and undisclosed changes made to its clinical trials schedule. In May, the company said it would start a Phase III trial next half of lead...
07:00 , May 14, 2007 |  BioCentury  |  Finance

Ebb & Flow

A few cancer vaccine companies and insiders managed to capitalize on rising share prices during the brief window between the March 29 FDA panel vote in favor of Dendreon's Provenge sipuleucel-T for prostate cancer and...
00:21 , May 12, 2007 |  BC Extra  |  Financial News

EndoCeutics amends IPO

EndoCeutics (Quebec City, Quebec) lowered the proposed price range of its IPO and now hopes to sell 5.8 million shares at $7-$9 instead of $11-$13 in an offering on NASDAQ. An $8 price would raise...
07:00 , Apr 2, 2007 |  BioCentury  |  Finance

IPO queue

IPO queue Company Filed Proposed shares To be raised (A) Price range Shares after Status (B) Amicus (C) 3/30/07 TBD Up to $86.3M TBD TBD Ph II Merrion (NASDAQ & Irish Enterprise Exchange) 3/30/07 TBD...
08:00 , Mar 5, 2007 |  BioCentury  |  Finance

IPOs line up

IPOs line up Proposed & updated Company Proposed shares To be raised (A) Price range Post-$ Status Cosmo Up to 3.4M CHF85.5M ($69.3M) CHF22-CHF28 CHF321.6-CHF409.3M ($260.8-$331.9M) Approved EndoCeutics TBD Up to $75M TBD TBD Ph...
02:00 , Mar 1, 2007 |  BC Extra  |  Financial News

EndoCeutics files for IPO

Hormone therapy company EndoCeutics (Quebec City, Quebec) filed to raise up to $75 million in an IPO on NASDAQ underwritten by First Albany; Oppenheimer; and Stifel, Nicolaus. In 2H07, EndoCeutics plans to start a Phase...